[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"news-1-m_and_a--":3,"news-meta":483},{"data":4,"pagination":479},[5,83,131,170,239,291,345,398,442],{"_id":6,"slug":7,"articleType":8,"body":9,"createdAt":17,"dek":18,"entities":19,"headline":38,"imageAlt":39,"imageUrl":40,"keyFacts":41,"language":68,"publishedAt":69,"seo":70,"sources":73,"summary":81,"updatedAt":82},"6a9fe50c5457399f4e5dcf8a","curaleaf-and-aurora-s-hostile-takeover-battle-escalates-over-valuations-and-control-287e0310","m_and_a",[10,11,12,13,14,15,16],"Curaleaf Holdings' takeover bid for Canadian rival Aurora Cannabis has escalated into a public dispute over financial projections, control of the combined entity, and whether the bid can legally close. Aurora's board reached its unanimous rejection decision on September 1. Aurora publicly announced that decision on September 2, and Curaleaf responded that day.","The process began with a virtual meeting between Aurora CEO Miguel Martin and Curaleaf CEO Boris Jordan on June 22. Curaleaf followed with an unpriced exclusivity request, then a non-binding proposal of approximately US$4.00 per share with a five-day ultimatum. Aurora rejected both, and Curaleaf went public with its intention on August 11, adding a US$5.00 cap.","Aurora's financial advisor, Fort Capital, concluded the offer was underpriced. Aurora's own analysis argues the bid sits 63% below its Canadian licensed-producer peer group on 2026 estimated revenue and 23% below on estimated EBITDA, after applying a 35% change-of-control premium. Aurora estimates a fair value of US$7.03 per share, 76% above the bid's base.","The dispute has also focused on shareholder control. Boris Jordan holds an 18% economic interest in Curaleaf but controls 69% of votes through multi-voting shares. Aurora argues its shareholders would hold only 7.7% of the combined company's equity and 3.2% of its votes if the deal proceeds.","Aurora's circular also lists structural defects in the bid. It claims Curaleaf's stated expiry of December 1 falls short of the 105-day minimum under Canadian securities law, that no French-language notice was published as required in Quebec, and that shareholders in 29 US states would receive only cash proceeds from a forced sale rather than Curaleaf shares.","The takeover is widely seen as a play for European dominance. Aurora's European medical revenue grew from C$41.0 million in fiscal 2024 to C$131.8 million in fiscal 2026, and it operates four EU-GMP-certified cultivation facilities. Curaleaf has said only about 20% of its international supply comes from its own facilities, and acquiring Aurora would help it reach its target of 50% to 75% internal supply.","Curaleaf's bid remains open until at least December 1, 2026, and Aurora is reportedly exploring alternative offers from unnamed third parties.","2026-09-08T10:35:56.886Z","Aurora's board unanimously rejected Curaleaf's unsolicited bid, triggering a public dispute over financial projections, shareholder control, and legal compliance.",{"brands":20,"products":23,"markets":24,"organizations":29},[21,22],"Curaleaf","Aurora Cannabis",[],[25,26,27,28],"Canada","Europe","UK","Germany",[30,22,31,32,33,34,35,36,37],"Curaleaf Holdings","Fort Capital","Torys LLP","TD Cowen","Internode Pharma","HAP Pharma","Cannara Biotech","Village Farms","Curaleaf and Aurora's Hostile Takeover Battle Escalates Over Valuations and Control","Curaleaf and Aurora Cannabis logos side by side with a gavel and financial charts in the background, symbolizing the hostile takeover battle.","",[42,46,50,53,56,59,62,65],{"claim":43,"sourceUrl":44,"_id":45},"Aurora's board reached its unanimous rejection decision on September 1, 2026, and announced it publicly on September 2.","https:\u002F\u002Fwww.protectaurora.com\u002F_files\u002Fugd\u002Fbd7041_217835cfb0644fae951f3752b2cfe098.pdf","6a9fe50c723e26a876df833d",{"claim":47,"sourceUrl":48,"_id":49},"Aurora's analysis argues the bid sits 63% below its Canadian licensed-producer peer group on 2026 estimated revenue and 23% below on 2026 estimated EBITDA, after applying a 35% change-of-control premium.","https:\u002F\u002Fbusinessofcannabis.com\u002Fcuraleaf-auroras-takeover-battle-votes-valuations-and-vitriol\u002F","6a9fe50c723e26a876df833e",{"claim":51,"sourceUrl":48,"_id":52},"Aurora estimates a fair value of US$7.03 per share, 76% above the bid's US$4.00 base and 41% above its US$5.00 cap.","6a9fe50c723e26a876df833f",{"claim":54,"sourceUrl":48,"_id":55},"Boris Jordan holds an 18% economic interest in Curaleaf but controls 69% of its votes through multi-voting shares.","6a9fe50c723e26a876df8340",{"claim":57,"sourceUrl":48,"_id":58},"Aurora shareholders would hold approximately 7.7% of the combined company's equity but only 3.2% of its votes.","6a9fe50c723e26a876df8341",{"claim":60,"sourceUrl":48,"_id":61},"Aurora alleges Curaleaf's stated expiry of December 1 falls short of the 105-day minimum under Canadian securities law, and that no French-language notice was published as required in Quebec.","6a9fe50c723e26a876df8342",{"claim":63,"sourceUrl":48,"_id":64},"Aurora's European medical revenue grew from C$41.0 million in fiscal 2024 to C$131.8 million in fiscal 2026, an 80% compound annual rate.","6a9fe50c723e26a876df8343",{"claim":66,"sourceUrl":48,"_id":67},"Curaleaf's management said only about 20% of its international supply comes from its own facilities, and it aims to increase this to 50% to 75% within six to 12 months.","6a9fe50c723e26a876df8344","en","2026-09-08T10:35:58.929Z",{"title":71,"description":72},"Curaleaf-Aurora Takeover Battle: Votes, Valuations, Vitriol","Aurora's board rejected Curaleaf's hostile bid, sparking a public fight over valuations, control, and legal compliance in the cannabis sector.",[74,78],{"name":75,"url":48,"trustTier":76,"_id":77},"Business of Cannabis","trade","6a9fe50c723e26a876df833c",{"name":79,"url":44,"trustTier":80},"Aurora Cannabis Directors Circular, September 1, 2026","company","Curaleaf Holdings' unsolicited takeover bid for Aurora Cannabis has turned into a public fight over valuation, control, and legal process. Aurora's board rejected the offer on September 2, arguing it undervalues the company by up to 76%. Both sides have traded accusations on social media and in shareholder circulars, while Aurora also claims the bid fails to meet Canadian securities law requirements.","2026-09-08T21:24:15.860Z",{"_id":84,"slug":85,"articleType":8,"body":86,"createdAt":93,"dek":94,"entities":95,"headline":105,"imageAlt":106,"imageUrl":40,"keyFacts":107,"language":68,"publishedAt":121,"seo":122,"sources":125,"summary":129,"updatedAt":130},"6a9ae8d95457399f4e5dcf1a","aurora-cannabis-urges-shareholders-to-reject-curaleaf-s-hostile-takeover-ea2bffa8",[87,88,89,90,91,92],"Aurora Cannabis Inc. is urging its shareholders to reject a hostile takeover bid announced last month by Curaleaf Holdings, Inc., according to The Canadian Press.","In a statement to shareholders, Aurora said it is debt-free and currently holds CA$149 million in cash, while Curaleaf has debts exceeding CA$1 billion.","Miguel Martin, Aurora’s CEO and executive chairman, said the takeover bid hopes to utilize Aurora shareholders’ own cash to help finance the deal and that the offer discounts Aurora’s assets.","Martin also said the takeover would shift the risks primarily onto shareholders.","Curaleaf chairman and chief executive Boris Jordan said he is ready and willing to discuss the merger but that Aurora has so far declined to engage meaningfully with the proposal.","Curaleaf announced its hostile takeover intentions for Aurora last month, offering cash and Curaleaf stock valued at $4 per Aurora share.","2026-09-04T15:50:49.279Z","The Canadian producer says Curaleaf’s bid undervalues its assets and would shift risk onto Aurora shareholders.",{"brands":96,"products":97,"markets":98,"organizations":102},[22,30],[],[99,100,101],"NASDAQ","TSX","OTCQX",[103,104],"Aurora Cannabis Inc.","Curaleaf Holdings, Inc.","Aurora Cannabis Urges Shareholders to Reject Curaleaf’s Hostile Takeover","Aurora Cannabis and Curaleaf Holdings corporate logos side by side during a hostile takeover dispute.",[108,112,115,118],{"claim":109,"sourceUrl":110,"_id":111},"Aurora Cannabis urged shareholders to reject Curaleaf Holdings’ hostile takeover bid.","https:\u002F\u002Fganjapreneur.com\u002Faurora-cannabis-urges-shareholders-to-reject-curaleafs-hostile-takeover\u002F","6a9ae8d9723e26a876d7fa18",{"claim":113,"sourceUrl":110,"_id":114},"Aurora said it is debt-free and holds CA$149 million in cash, while Curaleaf has debts exceeding CA$1 billion.","6a9ae8d9723e26a876d7fa19",{"claim":116,"sourceUrl":110,"_id":117},"Aurora CEO Miguel Martin said the bid would use Aurora shareholders’ own cash to help finance the deal and discounts Aurora’s assets.","6a9ae8d9723e26a876d7fa1a",{"claim":119,"sourceUrl":110,"_id":120},"Curaleaf offered cash and Curaleaf stock valued at $4 per Aurora share.","6a9ae8d9723e26a876d7fa1b","2026-09-04T15:50:50.643Z",{"title":123,"description":124},"Aurora Urges Rejection of Curaleaf Hostile Takeover","Aurora Cannabis asks shareholders to reject Curaleaf’s hostile takeover bid, saying the offer undervalues its assets and shifts risk onto shareholders.",[126],{"name":127,"url":110,"trustTier":76,"_id":128},"Ganjapreneur","6a9ae8d9723e26a876d7fa17","Aurora Cannabis Inc. is asking shareholders to reject a hostile takeover bid from Curaleaf Holdings, Inc., arguing the offer undervalues the company and would use Aurora’s own cash to help finance the deal.","2026-09-04T15:50:50.645Z",{"_id":132,"slug":133,"articleType":8,"body":134,"createdAt":138,"dek":139,"entities":140,"headline":148,"imageAlt":149,"imageUrl":40,"keyFacts":150,"language":68,"publishedAt":161,"seo":162,"sources":165,"summary":168,"updatedAt":169},"6a99d6665457399f4e5dcf09","cresco-labs-pays-50m-for-9-pennsylvania-medical-marijuana-stores-d03cebfc",[135,136,137],"Cresco Labs has completed a $50 million acquisition of nine medical marijuana stores in Pennsylvania, a move that cements its position as the state's top MMJ retailer and wholesaler, according to MJBizDaily.","The deal deepens Cresco's footprint in Pennsylvania, which is the second-largest medical cannabis market in the United States.","With the acquisition, Cresco now holds the No. 1 ranking among medical marijuana retailers and wholesalers in the state, strengthening its competitive position in a key East Coast market.","2026-09-03T20:19:50.773Z","The acquisition makes Cresco the top medical marijuana retailer and wholesaler in Pennsylvania, the second-largest U.S. medical cannabis market.",{"brands":141,"products":143,"markets":144,"organizations":146},[142],"Cresco",[],[145],"Pennsylvania",[147],"MJBizDaily","Cresco Labs Pays $50M for 9 Pennsylvania Medical Marijuana Stores","Cresco Labs medical marijuana dispensary storefront in Pennsylvania",[151,155,158],{"claim":152,"sourceUrl":153,"_id":154},"Cresco paid $50 million for nine Pennsylvania medical marijuana stores.","https:\u002F\u002Fmjbizdaily.com\u002Fnews\u002Fmso-cresco-pays-50m-for-9-pennsylvania-mmj-stores\u002F617878\u002F","6a99d666723e26a876d6e369",{"claim":156,"sourceUrl":153,"_id":157},"The deal makes Cresco Pennsylvania's No. 1 MMJ retailer and wholesaler.","6a99d666723e26a876d6e36a",{"claim":159,"sourceUrl":153,"_id":160},"Pennsylvania is the second-largest U.S. medical cannabis market.","6a99d666723e26a876d6e36b","2026-09-03T20:19:52.460Z",{"title":163,"description":164},"Cresco Pays $50M for 9 Pennsylvania MMJ Stores","Cresco Labs acquires nine Pennsylvania medical marijuana stores for $50 million, becoming the state's top MMJ retailer and wholesaler.",[166],{"name":147,"url":153,"trustTier":76,"_id":167},"6a99d666723e26a876d6e368","Cresco Labs has acquired nine medical marijuana dispensaries in Pennsylvania for $50 million, positioning the multistate operator as the state's leading MMJ retailer and wholesaler.","2026-09-03T20:19:52.461Z",{"_id":171,"slug":172,"articleType":8,"body":173,"createdAt":182,"dek":183,"entities":184,"headline":204,"imageAlt":205,"imageUrl":40,"keyFacts":206,"language":68,"publishedAt":229,"seo":230,"sources":233,"summary":237,"updatedAt":238},"6a91c47aaeddfad21a39fa01","federal-rescheduling-sets-the-stage-for-marijuana-business-acquisitions-as-pharma-and-ag-firms-eye-industry-59c8b27d",[174,175,176,177,178,179,180,181],"The April 23 federal rescheduling order is not a story of overnight legalization but of careful planning and targeted consolidation, according to an op-ed by Christopher B. Lynch, a member at Dickinson Wright PLLC. Since Acting Attorney General Todd Blanche moved FDA-approved and state-licensed medical marijuana products from Schedule I to Schedule III of the Controlled Substances Act, the best-positioned businesses are not celebrating but preparing to seize new first-mover opportunities.","The order reclassified medical marijuana that is FDA-approved or state-licensed, moving it out of Schedule I—reserved for drugs deemed to have no accepted medical use—and into Schedule III, the category for substances with accepted medical use and lower abuse potential. Blanche limited the order to medical products, citing U.S. international drug treaty obligations as the reason adult-use marijuana remained on Schedule I.","Licensed operators received a 60-day window to opt into a priority DEA registration pathway. In June, Trulieve restructured to separate its 206 DEA-registered medical dispensaries from its adult-use business and became the first U.S. cannabis company to list on the New York Stock Exchange, demonstrating that registration can open access to markets and resources previously unavailable to the industry.","Tax relief under Section 280E—which prevents deductions for operations that sell Schedule I and II drugs—is the clearest near-term benefit of registration, but there are also arguments for federal trademark protection and other prospective benefits. Meanwhile, the broader question of full rescheduling was the subject of a separate DOJ administrative hearing that ran from June 29 through July 15, with final briefs filed August 19 and a recommendation pending from Chief Administrative Law Judge Derek C. Julius.","Legal challenges add uncertainty. What began as a single petition by Smart Approaches to Marijuana has become three consolidated lawsuits in the D.C. Circuit, plus a coalition of doctors, activists, and the attorneys general of Indiana and Nebraska. Plaintiffs have asked the court to stay the order while the case proceeds, and a ruling granting a stay could freeze DEA registrations and potentially suspend benefits that operators are banking on.","State law compounds the complexity, since no two states built their systems alike. Oklahoma has already tied state licensure to DEA registration, telling license holders to get DEA registration or risk losing their state permits next year. New DEA regulation of license holders could mean on-demand facility access and inspection authority, DEA security requirements, mandatory disclosure of employees' Social Security numbers, and potential exposure for co-located medical and adult-use businesses.","Rescheduling alone is not expected to turn cannabis equities into gold overnight, and institutional capital is unlikely to dive in immediately without congressional legislation such as the SAFER Banking Act. But in the meantime, rescheduling is drawing interest from pharmaceutical, agricultural, and consumer products companies that stayed on the sidelines while marijuana sat on Schedule I, and well-positioned operators are already using this window to plan restructurings, seek new partners, acquire distressed assets, and target new markets.","The practical question, Lynch writes, is whether a business is positioned to be a consolidator, an attractive acquisition target, or something different, and the race for pole position is already underway.","2026-08-28T17:25:14.986Z","An op-ed argues that the April federal rescheduling order is accelerating a quiet wave of cannabis consolidation, with pharma and agricultural companies positioning for first-mover advantages.",{"brands":185,"products":187,"markets":188,"organizations":194},[186],"Trulieve",[],[189,190,191,192,193],"US","Oklahoma","Maryland","Michigan","Washington",[195,196,197,198,199,200,201,202,203],"NewLake Capital Partners","Dickinson Wright PLLC","FDA","DEA","DOJ","MMJ International Holdings","MedPharm Iowa","Tri-Mountain Pure","Smart Approaches to Marijuana","Federal Rescheduling Sets the Stage for Marijuana Business Acquisitions as Pharma and Ag Firms Eye Industry","Cannabis business consolidation concept with pharmaceutical and agricultural company logos approaching a marijuana leaf on a chessboard.",[207,211,214,217,220,223,226],{"claim":208,"sourceUrl":209,"_id":210},"The April 23 federal order moved FDA-approved and state-licensed medical marijuana products from Schedule I to Schedule III of the Controlled Substances Act.","https:\u002F\u002Fwww.marijuanamoment.net\u002Ffederal-rescheduling-sets-the-stage-for-marijuana-business-acquisitions-as-pharma-and-ag-firms-eye-industry-op-ed\u002F","6a91c47a0385656fb2e2c313",{"claim":212,"sourceUrl":209,"_id":213},"Licensed operators received a 60-day window to opt into a priority DEA registration pathway.","6a91c47a0385656fb2e2c314",{"claim":215,"sourceUrl":209,"_id":216},"Trulieve restructured to separate its 206 DEA-registered medical dispensaries from its adult-use business and became the first U.S. cannabis company to list on the New York Stock Exchange.","6a91c47a0385656fb2e2c315",{"claim":218,"sourceUrl":209,"_id":219},"Tax relief under Section 280E is the clearest near-term benefit of registration.","6a91c47a0385656fb2e2c316",{"claim":221,"sourceUrl":209,"_id":222},"Three consolidated lawsuits in the D.C. Circuit challenge the rescheduling move, with plaintiffs asking the court to stay the order while the case proceeds.","6a91c47a0385656fb2e2c317",{"claim":224,"sourceUrl":209,"_id":225},"Oklahoma has tied state licensure to DEA registration, telling license holders to get DEA registration or risk losing their state permits next year.","6a91c47a0385656fb2e2c318",{"claim":227,"sourceUrl":209,"_id":228},"Rescheduling is drawing interest from pharmaceutical, agricultural, and consumer products companies that stayed on the sidelines while marijuana sat on Schedule I.","6a91c47a0385656fb2e2c319","2026-08-28T17:25:16.521Z",{"title":231,"description":232},"Federal Rescheduling Sets Stage for Cannabis M&A","The April federal rescheduling order is accelerating cannabis consolidation as pharma and ag firms eye the industry, according to an op-ed.",[234],{"name":235,"url":209,"trustTier":76,"_id":236},"Marijuana Moment","6a91c47a0385656fb2e2c312","The April 23 federal order moving FDA-approved and state-licensed medical marijuana from Schedule I to Schedule III is driving targeted consolidation in the cannabis industry, according to an op-ed by Christopher B. Lynch of Dickinson Wright PLLC. Rather than immediate legalization, the change is prompting operators to restructure, seek partners, and acquire distressed assets while pharmaceutical and agricultural firms evaluate entry.","2026-08-28T17:25:16.525Z",{"_id":240,"slug":241,"articleType":8,"body":242,"createdAt":250,"dek":251,"entities":252,"headline":263,"imageAlt":264,"imageUrl":40,"keyFacts":265,"language":68,"publishedAt":282,"seo":283,"sources":286,"summary":289,"updatedAt":290},"6a9097d8aeddfad21a39f9d3","aurora-cannabis-buys-uk-pharmacy-and-import-licence-for-2-1m-124d24b8",[243,244,245,246,247,248,249],"Aurora Cannabis has completed dual acquisitions in the UK worth £2.1m, taking direct ownership of a licensed importer and wholesaler alongside a licensed pharmacy for the first time in what it calls 'a very important growth market'. On August 19, 2026, the Canadian LP acquired 100% of the shares in Birmingham-based Internod Pharma and HAP Pharma in an all-cash deal.","Andreas Dotterweich, Aurora's Senior Vice President, said the acquisition was designed to shorten the distance between the company and the UK's patient population. 'It is being a lot closer to the patient,' he said. 'At the end of the day, it's patient demand, and you want to have a direct route to the patient, and the direct route to market… it gives us also control and ownership of the key import, distribution, and pharmacy capabilities.'","Internod Pharma holds UK Wholesale Dealer's Authorisation 58825, granted by the MHRA on August 14, 2024, covering the import, holding and supply of prescription-only medicines, including narcotic and psychotropic products, from an operating site in Oldbury. That licence is the key asset behind the acquisition, giving Aurora the right to import and distribute medical cannabis product into the UK without routing them through a third-party wholesaler.","HAP Pharma is described as 'a licensed pharmacy', but has filed dormant company accounts since incorporation in April 2020, suggesting no significant trading activity. Internod Pharma's latest accounts show £30,872 in equipment at cost by March 2026, trade creditors, and a small debtor book, though its turnover has never been made public.","The acquisition follows a period of rapid growth in Aurora's European business. Europe accounted for 47.5% of Aurora's net revenue in the quarter ended June 30, 2026, up from 33.7% a year earlier, while Canada's share fell from 49.9% to 35.9% over the same period. Germany drove the shift, with Aurora's international medical cannabis revenue rising 17% to CA$43.3m.","CEO Miguel Martin said the transaction marked the latest evolution of Aurora's long-term strategy, moving away from Canadian adult-use markets towards medical cannabis markets flourishing across Europe. 'We believe that this transaction will allow us to fully leverage our operational, commercial and regulatory expertise to expand our market share, while also supporting a consistent and reliable supply of high-quality medical cannabis products to UK patients,' Martin explained.","Asked whether the deal would translate into lower prices for patients, Dotterweich said it was 'a bit early to give a concrete answer to that', but that it meant 'better access for the patients, definitely, also especially with the pharmacy'. He emphasised that the UK is 'a very important growth market for Aurora' and that the acquisition strengthens Aurora's platform to navigate regulatory shifts.","2026-08-27T20:02:32.313Z","The Canadian producer acquires Internod Pharma and HAP Pharma to secure direct import, distribution, and pharmacy capabilities in the UK medical cannabis market.",{"brands":253,"products":255,"markets":256,"organizations":258},[22,30,254],"Safari Flower Company",[],[27,28,25,257],"Poland",[259,35,260,75,261,262],"Internod Pharma","MHRA","Zuanic & Associates","Veterans Affairs Canada","Aurora Cannabis Buys UK Pharmacy and Import Licence for £2.1m","Aurora Cannabis signage outside a UK pharmacy, representing the company's £2.1m acquisition of Internod Pharma and HAP Pharma to secure direct patient access.",[266,270,273,276,279],{"claim":267,"sourceUrl":268,"_id":269},"Aurora Cannabis acquired 100% of Internod Pharma and HAP Pharma in an all-cash deal worth £2.1m on August 19, 2026.","https:\u002F\u002Fbusinessofcannabis.com\u002Faurora-buys-uk-pharmacy-and-import-licence-for-2-1m-securing-direct-route-to-patients\u002F","6a9097d8e81f0249cd72d3cc",{"claim":271,"sourceUrl":268,"_id":272},"Internod Pharma holds UK Wholesale Dealer's Authorisation 58825, granted by the MHRA on August 14, 2024, covering the import, holding and supply of prescription-only medicines including narcotic and psychotropic products.","6a9097d8e81f0249cd72d3cd",{"claim":274,"sourceUrl":268,"_id":275},"Europe accounted for 47.5% of Aurora's net revenue in the quarter ended June 30, 2026, up from 33.7% a year earlier.","6a9097d8e81f0249cd72d3ce",{"claim":277,"sourceUrl":268,"_id":278},"Aurora's international medical cannabis revenue rose 17% to CA$43.3m, with growth concentrated in Germany.","6a9097d8e81f0249cd72d3cf",{"claim":280,"sourceUrl":268,"_id":281},"HAP Pharma has filed dormant company accounts since incorporation in April 2020, suggesting no significant trading activity.","6a9097d8e81f0249cd72d3d0","2026-08-28T05:26:14.544Z",{"title":284,"description":285},"Aurora Buys UK Pharmacy and Import Licence for £2.1m","Aurora Cannabis acquires Internod Pharma and HAP Pharma for £2.1m, securing direct import, distribution, and pharmacy capabilities in the UK medical cannabis market.",[287],{"name":75,"url":268,"trustTier":76,"_id":288},"6a9097d8e81f0249cd72d3cb","Aurora Cannabis has acquired 100% of Birmingham-based Internod Pharma and HAP Pharma in an all-cash deal worth £2.1m, giving it direct ownership of a licensed importer, wholesaler, and pharmacy in the UK for the first time. The deal, announced on August 19, 2026, is designed to shorten the distance between Aurora and UK patients as the company shifts focus from Canadian adult-use to European medical cannabis markets.","2026-08-28T05:26:14.622Z",{"_id":292,"slug":293,"articleType":8,"body":294,"createdAt":303,"dek":304,"entities":305,"headline":315,"imageAlt":316,"imageUrl":40,"keyFacts":317,"language":68,"publishedAt":282,"seo":337,"sources":340,"summary":343,"updatedAt":344},"6a9097fcaeddfad21a39f9d4","aurora-accuses-curaleaf-of-pressuring-shareholders-as-official-takeover-bid-launches-6d25d076",[295,296,297,298,299,300,301,302],"Curaleaf Holdings formally launched its unsolicited takeover bid for Aurora Cannabis on August 18, 2026, giving Aurora shareholders until December 1, 2026 to decide whether to tender their shares.","The offer combines 0.3463 of a Curaleaf share and US$0.75 in cash for each Aurora share, together worth US$4.00, representing a 45% premium to Aurora's unaffected 30-day volume-weighted price of US$2.75, or 110% once Aurora's cash pile is stripped out.","Aurora's board has formed a special committee of independent directors and urged shareholders to take no action before it makes a formal recommendation, expected within 15 days of the bid's launch, around September 2.","Aurora CEO Miguel Martin accused Curaleaf of making its offer public to pressure shareholders into a short-term decision for the benefit of Curaleaf shareholders, stating that Curaleaf's objective is to acquire Aurora's EU-GMP facilities and medical cannabis platforms at the lowest price possible.","Curaleaf's Boris Jordan defended the bid price by citing significant headwinds for Aurora in Canada and Germany, including the cancellation of German medical cannabis reimbursement and reduced Canadian medical cannabis reimbursement rates.","For the deal to close, more than half of Aurora's shareholders need to agree to sell, not counting Curaleaf's own stake, and at least two-thirds of Aurora's shares overall, including potential share conversions, must be tendered under Canadian rules.","Curaleaf says there is no financing or due-diligence condition attached to the offer, only regulatory approvals and standard closing terms, including that Aurora's shareholder rights plan, if adopted, must not interfere.","On the same day as the bid launch, Aurora announced a £2.1 million acquisition of Internode Pharma and HAP Pharma, a licensed importer and pharmacy in Birmingham, giving it direct ownership of the UK supply chain from import through to patient dispensing.","2026-08-27T20:03:08.543Z","Curaleaf has formally launched its unsolicited bid for Aurora Cannabis, setting a December 1 deadline while Aurora urges shareholders to take no action.",{"brands":306,"products":307,"markets":308,"organizations":309},[21,22],[],[25,28,27],[30,22,310,261,32,311,312,313,314,34,35],"Prohibition Partners","Stikeman Elliott","Paul, Weiss","Fort Capital Partners","Kingsdale Advisors","Aurora Accuses Curaleaf of Pressuring Shareholders as Official Takeover Bid Launches","Curaleaf and Aurora Cannabis corporate logos side by side, representing the unsolicited takeover bid.",[318,322,325,328,331,334],{"claim":319,"sourceUrl":320,"_id":321},"Curaleaf formally launched its takeover bid for Aurora Cannabis on August 18, 2026, with the offer open until December 1, 2026.","https:\u002F\u002Fbusinessofcannabis.com\u002Faurora-accuses-curaleaf-of-pressuring-shareholders-as-it-launches-official-takeover-bid\u002F","6a9097fce81f0249cd72d42b",{"claim":323,"sourceUrl":320,"_id":324},"Curaleaf's offer combines 0.3463 of a Curaleaf share and US$0.75 in cash for each Aurora share, together worth US$4.00, a 45% premium to Aurora's unaffected 30-day volume-weighted price.","6a9097fce81f0249cd72d42c",{"claim":326,"sourceUrl":320,"_id":327},"Aurora's board has urged shareholders to take no action before it makes a formal recommendation, expected within 15 days of the bid's launch.","6a9097fce81f0249cd72d42d",{"claim":329,"sourceUrl":320,"_id":330},"Aurora CEO Miguel Martin accused Curaleaf of making its offer public to pressure shareholders into making a short-term decision for the benefit of Curaleaf shareholders.","6a9097fce81f0249cd72d42e",{"claim":332,"sourceUrl":320,"_id":333},"The bid values Aurora at roughly US$236 million on a basic-share basis, though that could change once outstanding options and warrants are counted.","6a9097fce81f0249cd72d42f",{"claim":335,"sourceUrl":320,"_id":336},"Aurora announced a £2.1 million acquisition of Internode Pharma and HAP Pharma, giving it direct ownership of the UK supply chain from import through to patient dispensing.","6a9097fce81f0249cd72d430",{"title":338,"description":339},"Aurora Accuses Curaleaf of Pressuring Shareholders","Curaleaf launches official takeover bid for Aurora Cannabis, offering US$4.00 per share. Aurora urges shareholders to take no action pending review.",[341],{"name":75,"url":320,"trustTier":76,"_id":342},"6a9097fce81f0249cd72d42a","Curaleaf Holdings has submitted an official takeover bid for Aurora Cannabis, offering 0.3463 Curaleaf shares plus US$0.75 cash per Aurora share, valued at roughly US$236 million. Aurora's board has told shareholders to take no action pending a formal recommendation expected around September 2, while CEO Miguel Martin accused Curaleaf of pressuring shareholders into a short-term decision.","2026-08-28T05:26:14.629Z",{"_id":346,"slug":347,"articleType":8,"body":348,"createdAt":355,"dek":356,"entities":357,"headline":368,"imageAlt":369,"imageUrl":40,"keyFacts":370,"language":68,"publishedAt":282,"seo":390,"sources":393,"summary":396,"updatedAt":397},"6a909898aeddfad21a39f9d8","curaleaf-s-unsolicited-aurora-bid-targets-europe-s-medical-cannabis-leadership-5b5f7183",[349,350,351,352,353,354],"Curaleaf Holdings has launched an unsolicited takeover bid for rival Aurora Cannabis, a move that would reshape the European medical cannabis landscape. On August 11, Curaleaf informed investors of its intention to offer US$4.00 per share for all issued and outstanding Aurora shares, a proposal Chairman and CEO Boris Jordan called a 'win-win' for both sets of shareholders.","Aurora responded within hours, disputing Curaleaf's account of their private discussions and confirming that its board would form a special committee of independent directors to evaluate the proposal. The offer combines 0.3463 of a Curaleaf share and US$0.75 in cash for each Aurora share, representing a 45% premium to Aurora's 30-day volume-weighted average price of US$2.75. Excluding cash on Aurora's balance sheet, Curaleaf calculates the premium at 110%.","Based on 58.9 million Aurora shares outstanding as of March 31, 2026, the bid values Aurora at approximately US$236 million on a basic-share basis. That figure is modest compared with earlier industry deals: Aphria's 2020 merger with Tilray was worth roughly US$3.9 billion, and Aurora's own 2018 purchase of MedReleaf was reported at between US$2.5 billion and US$3.2 billion. It is also the first hostile approach by a leading cannabis company since Green Growth Brands' failed 2019 bid for Aphria.","The strategic logic centres on Europe, where medical cannabis sales are forecast by Prohibition Partners to more than double by 2028. Aurora has pivoted almost entirely to international medical cannabis, with medical operations accounting for 90% of full-year revenue. The company holds the number one market share position in Poland, operates EU-GMP certified manufacturing through its Pedanios unit in Germany, and has secured EU Community Plant Variety Rights for two proprietary strains.","Curaleaf's international arm posted US$172.5 million in revenue for 2025, up 63% year-on-year, driven by its position as Germany's largest single flower supplier and its UK clinic network. Jordan said the combination would unlock at least US$40 million in annual cost and revenue synergies, creating a pro forma company with trailing 12-month revenue of US$1.5 billion and adjusted EBITDA of US$350 million across 17 countries.","Aurora's shares rose 22% to US$3.48 on the day of the announcement and added a further 9.61% the following session to US$3.82, still below the US$4.00 offer price. Analysts at TD Cowen wrote that the offer 'does not fully capture Aurora's long-term intrinsic value,' citing its medical cannabis leadership and genetics portfolio. Aurora's special committee review is the next milestone to watch.","2026-08-27T20:05:44.096Z","A US$236 million hostile offer would combine two of the continent's largest medical cannabis operators, but Aurora's board is not yet convinced.",{"brands":358,"products":360,"markets":362,"organizations":367},[21,22,359,254],"Pedanios",[361],"QMID inhalation device",[28,257,27,363,364,365,25,366],"France","Spain","Turkey","Portugal",[33,310],"Curaleaf's Unsolicited Aurora Bid Targets Europe's Medical Cannabis Leadership","Curaleaf and Aurora Cannabis logos side by side, representing a potential merger in the European medical cannabis market.",[371,375,378,381,384,387],{"claim":372,"sourceUrl":373,"_id":374},"Curaleaf announced an unsolicited takeover bid for Aurora Cannabis at US$4.00 per share on August 11.","https:\u002F\u002Fbusinessofcannabis.com\u002Fcuraleafs-aurora-bid-is-a-fight-for-europes-cannabis-crown\u002F","6a909898e81f0249cd72d66a",{"claim":376,"sourceUrl":373,"_id":377},"The offer values Aurora at roughly US$236 million based on 58.9 million shares outstanding.","6a909898e81f0249cd72d66b",{"claim":379,"sourceUrl":373,"_id":380},"Aurora's board formed a special committee of independent directors to review the proposal.","6a909898e81f0249cd72d66c",{"claim":382,"sourceUrl":373,"_id":383},"Aurora's medical operations accounted for 90% of full-year revenue, with the number one market share position in Poland.","6a909898e81f0249cd72d66d",{"claim":385,"sourceUrl":373,"_id":386},"Curaleaf International posted US$172.5 million in 2025 revenue, up 63% year-on-year, driven by Germany and the UK.","6a909898e81f0249cd72d66e",{"claim":388,"sourceUrl":373,"_id":389},"TD Cowen analysts said the offer does not fully capture Aurora's long-term intrinsic value.","6a909898e81f0249cd72d66f",{"title":391,"description":392},"Curaleaf's Aurora Bid Targets Europe's Cannabis Crown","Curaleaf's US$236M unsolicited bid for Aurora Cannabis aims to consolidate European medical cannabis leadership, but Aurora's board is reviewing the offer.",[394],{"name":75,"url":373,"trustTier":76,"_id":395},"6a909898e81f0249cd72d669","Curaleaf Holdings announced an unsolicited takeover bid for Aurora Cannabis at US$4.00 per share, valuing the deal at roughly US$236 million. The move aims to consolidate leading positions in Germany, Poland, and the UK, but Aurora has formed a special committee to review the offer, and analysts say the price may undervalue Aurora's medical cannabis franchise.","2026-08-28T05:26:14.648Z",{"_id":399,"slug":400,"articleType":8,"body":401,"createdAt":407,"dek":408,"entities":409,"headline":418,"imageAlt":419,"imageUrl":40,"keyFacts":420,"language":68,"publishedAt":282,"seo":434,"sources":437,"summary":440,"updatedAt":441},"6a90991faeddfad21a39f9dc","jars-cannabis-to-acquire-sonoran-roots-creating-arizona-s-largest-dispensary-network-078d231a",[402,403,404,405,406],"JARS Cannabis has announced plans to acquire Sonoran Roots in a deal that would create the largest cannabis dispensary network in Arizona, totaling 27 locations.","As part of the acquisition, Sonoran Roots’ eight Ponderosa Dispensary locations in Chandler, Flagstaff, Glendale, Mesa, Phoenix, Queen Creek, Tempe, and Tucson will rebrand under the JARS Cannabis name.","Ronnie Kassab, CEO of JARS Cannabis, said the acquisition is “not scale for scale’s sake,” describing the combination as bringing together JARS’ retail platform with Sonoran Roots’ brand, product portfolio, and vertically integrated operation.","Michael O’Brien, currently CEO of Sonoran Roots, will become chief strategy officer of JARS. He said the companies are preserving their brands and relationships while pairing Sonoran Roots’ strengths with a retail organization that has the scale and ambition to expand further.","The transaction is expected to close by the end of the third quarter of this year and remains subject to customary closing conditions and regulatory approvals.","2026-08-27T20:07:59.887Z","The deal will rebrand eight Ponderosa Dispensary locations under JARS Cannabis and form a 27-store network across Arizona.",{"brands":410,"products":414,"markets":415,"organizations":417},[411,412,413],"JARS Cannabis","Sonoran Roots","Ponderosa Dispensary",[],[416],"Arizona",[411,412],"JARS Cannabis to Acquire Sonoran Roots, Creating Arizona’s Largest Dispensary Network","JARS Cannabis and Sonoran Roots logos alongside a map of Arizona showing the 27-dispensary network.",[421,425,428,431],{"claim":422,"sourceUrl":423,"_id":424},"JARS Cannabis is set to acquire Sonoran Roots to create a network of 27 dispensaries, the largest cannabis dispensary network in Arizona.","https:\u002F\u002Fganjapreneur.com\u002Fjars-cannabis-to-acquire-sonoran-roots-creating-arizonas-largest-dispensary-network\u002F","6a90991fe81f0249cd72d7b4",{"claim":426,"sourceUrl":423,"_id":427},"Sonoran Roots’ eight Ponderosa Dispensary locations in Chandler, Flagstaff, Glendale, Mesa, Phoenix, Queen Creek, Tempe, and Tucson will rebrand under the JARS Cannabis name.","6a90991fe81f0249cd72d7b5",{"claim":429,"sourceUrl":423,"_id":430},"Michael O’Brien, currently CEO of Sonoran Roots, will become the chief strategy officer of JARS.","6a90991fe81f0249cd72d7b6",{"claim":432,"sourceUrl":423,"_id":433},"The transaction is expected to close by the end of the third quarter of this year and is subject to customary closing conditions and regulatory approvals.","6a90991fe81f0249cd72d7b7",{"title":435,"description":436},"JARS Cannabis to Acquire Sonoran Roots in Arizona","JARS Cannabis will acquire Sonoran Roots, rebranding eight Ponderosa Dispensary locations and creating Arizona’s largest dispensary network with 27 stores.",[438],{"name":127,"url":423,"trustTier":76,"_id":439},"6a90991fe81f0249cd72d7b3","JARS Cannabis is set to acquire Sonoran Roots, combining its retail platform with Sonoran Roots’ vertically integrated operation and eight Ponderosa Dispensary locations. The transaction is expected to close by the end of the third quarter, subject to customary conditions and regulatory approvals.","2026-08-28T05:26:14.667Z",{"_id":443,"slug":444,"articleType":8,"body":445,"createdAt":449,"dek":450,"entities":451,"headline":457,"imageAlt":458,"imageUrl":40,"keyFacts":459,"language":68,"publishedAt":282,"seo":470,"sources":473,"summary":477,"updatedAt":478},"6a909a3aaeddfad21a39f9e5","aurora-cannabis-rejects-curaleaf-s-acquisition-claims-tells-shareholders-to-wait-0c90388f",[446,447,448],"Aurora Cannabis has issued a direct rebuttal to U.S. cannabis company Curaleaf following the American operator's public statements about its attempt to acquire the Canadian producer. The response marks a sharp escalation in what appears to be an unsolicited takeover effort.","In its message, Aurora is urging shareholders to hold off on taking any action related to Curaleaf's approach. The company's leadership is disputing the claims made by Curaleaf, though specific details of the disagreement were not outlined in the initial report.","The dispute pits one of Canada's most prominent licensed producers against a major U.S. multi-state operator, highlighting the ongoing cross-border tensions and consolidation pressures within the global cannabis industry.","2026-08-27T20:12:42.212Z","The Canadian producer disputes the U.S. operator's public statements about a takeover approach and urges investors not to act prematurely.",{"brands":452,"products":453,"markets":454,"organizations":456},[22,21],[],[25,455],"United States",[],"Aurora Cannabis Rejects Curaleaf's Acquisition Claims, Tells Shareholders to Wait","Aurora Cannabis and Curaleaf corporate logos side by side, representing a disputed acquisition attempt between the Canadian and U.S. cannabis companies.",[460,464,467],{"claim":461,"sourceUrl":462,"_id":463},"Aurora Cannabis is publicly responding to Curaleaf's efforts to acquire the company.","https:\u002F\u002Fstratcann.com\u002Fnews\u002Faurora-cannabis-fires-back-curaleafs-claims-urges-shareholders-wait\u002F","6a909a3ae81f0249cd72da61",{"claim":465,"sourceUrl":462,"_id":466},"Aurora Cannabis is urging its shareholders to wait before responding to Curaleaf's approach.","6a909a3ae81f0249cd72da62",{"claim":468,"sourceUrl":462,"_id":469},"Curaleaf is a U.S. cannabis company that has made claims regarding its acquisition efforts targeting Aurora Cannabis.","6a909a3ae81f0249cd72da63",{"title":471,"description":472},"Aurora Cannabis Rejects Curaleaf Acquisition Claims","Aurora Cannabis disputes Curaleaf's takeover claims and urges shareholders to wait before responding to the U.S. operator's approach.",[474],{"name":475,"url":462,"trustTier":76,"_id":476},"StratCann","6a909a3ae81f0249cd72da60","Aurora Cannabis is publicly pushing back against Curaleaf's claims regarding the American company's efforts to acquire the Canadian licensed producer. Aurora is urging its shareholders to wait before responding to any overtures, signaling a contentious start to the unsolicited approach.","2026-08-28T05:26:14.720Z",{"page":480,"limit":481,"total":482,"pages":480},1,18,9,{"data":484},{"types":485,"markets":511,"brands":655,"latestPublishedAt":772},[486,489,492,493,495,498,501,503,506,508],{"value":487,"count":488},"regulation",35,{"value":490,"count":491},"market",25,{"value":8,"count":482},{"value":494,"count":482},"research",{"value":496,"count":497},"enforcement",6,{"value":499,"count":500},"licensing",4,{"value":502,"count":500},"finance",{"value":504,"count":505},"brand_launch",3,{"value":507,"count":505},"other",{"value":509,"count":510},"product_launch",2,[512,514,516,519,520,521,522,524,526,527,528,530,532,533,535,537,538,540,542,543,544,546,548,550,552,554,556,558,559,560,562,564,566,568,569,571,573,574,576,578,580,582,584,586,588,590,592,594,595,597,599,600,602,604,606,608,610,611,612,614,616,618,619,621,623,625,627,629,631,633,635,637,639,641,643,645,647,649,651,653],{"value":189,"count":513},19,{"value":25,"count":515},15,{"value":517,"count":518},"California",11,{"value":28,"count":518},{"value":27,"count":482},{"value":192,"count":497},{"value":523,"count":497},"Illinois",{"value":525,"count":497},"Colorado",{"value":455,"count":497},{"value":364,"count":500},{"value":529,"count":500},"Australia",{"value":531,"count":500},"New York",{"value":363,"count":505},{"value":534,"count":505},"Massachusetts",{"value":536,"count":505},"South Africa",{"value":193,"count":505},{"value":539,"count":505},"Montana",{"value":541,"count":505},"Texas",{"value":257,"count":505},{"value":366,"count":505},{"value":545,"count":510},"North Carolina",{"value":547,"count":510},"Nebraska",{"value":549,"count":510},"Alabama",{"value":551,"count":510},"Ohio",{"value":553,"count":510},"Thailand",{"value":555,"count":510},"Washington State",{"value":557,"count":510},"Rhode Island",{"value":145,"count":510},{"value":416,"count":510},{"value":561,"count":510},"Virginia",{"value":563,"count":510},"Delaware",{"value":565,"count":510},"Maine",{"value":567,"count":510},"US federal",{"value":191,"count":510},{"value":570,"count":510},"Kentucky",{"value":572,"count":510},"Minnesota",{"value":26,"count":510},{"value":575,"count":480},"Brazil",{"value":577,"count":480},"Global",{"value":579,"count":480},"Argentina",{"value":581,"count":480},"Sacramento, California",{"value":583,"count":480},"Oregon",{"value":585,"count":480},"District of Columbia",{"value":587,"count":480},"New Mexico",{"value":589,"count":480},"CBD",{"value":591,"count":480},"North America",{"value":593,"count":480},"hemp market",{"value":99,"count":480},{"value":596,"count":480},"Latin America",{"value":598,"count":480},"Humboldt County, California",{"value":100,"count":480},{"value":601,"count":480},"EU",{"value":603,"count":480},"Connecticut",{"value":605,"count":480},"New Hampshire",{"value":607,"count":480},"New Jersey",{"value":609,"count":480},"Wisconsin",{"value":101,"count":480},{"value":190,"count":480},{"value":613,"count":480},"San Francisco",{"value":615,"count":480},"Ireland",{"value":617,"count":480},"retail cannabis",{"value":365,"count":480},{"value":620,"count":480},"Washington, D.C.",{"value":622,"count":480},"CA",{"value":624,"count":480},"Florida",{"value":626,"count":480},"Utah",{"value":628,"count":480},"medical cannabis",{"value":630,"count":480},"cannabis",{"value":632,"count":480},"India",{"value":634,"count":480},"Indiana",{"value":636,"count":480},"Missouri",{"value":638,"count":480},"Houston",{"value":640,"count":480},"Colombia",{"value":642,"count":480},"BC",{"value":644,"count":480},"Chile",{"value":646,"count":480},"Georgia",{"value":648,"count":480},"Mississippi",{"value":650,"count":480},"Wyoming",{"value":652,"count":480},"hemp",{"value":654,"count":480},"North Macedonia",[656,657,658,660,661,662,664,666,668,670,672,674,676,678,680,682,684,686,687,689,691,693,694,696,697,699,701,703,705,707,709,711,713,715,717,719,721,723,725,727,729,730,731,733,735,737,739,741,742,744,746,748,750,752,754,756,757,759,761,763,765,767,769,770],{"value":22,"count":497},{"value":21,"count":500},{"value":659,"count":510},"Target",{"value":30,"count":510},{"value":254,"count":510},{"value":663,"count":480},"Cova Software",{"value":665,"count":480},"High Tide",{"value":667,"count":480},"Total Wine & More",{"value":669,"count":480},"Epidiolex",{"value":671,"count":480},"Callie's Apothecary",{"value":673,"count":480},"Sativex",{"value":675,"count":480},"Blunt Brunch",{"value":677,"count":480},"Tweed",{"value":679,"count":480},"WaterClear THC",{"value":681,"count":480},"PPX",{"value":683,"count":480},"Lotus Farmacy",{"value":685,"count":480},"Lovewell Farms",{"value":359,"count":480},{"value":688,"count":480},"Terps USA",{"value":690,"count":480},"iAnthus",{"value":692,"count":480},"Cannabis Europa",{"value":413,"count":480},{"value":695,"count":480},"Mind Forward",{"value":411,"count":480},{"value":698,"count":480},"Claybourne",{"value":700,"count":480},"Trulieve Inc.",{"value":702,"count":480},"Blue Sage",{"value":704,"count":480},"Jetty",{"value":706,"count":480},"Remexian",{"value":708,"count":480},"Vertanical",{"value":710,"count":480},"Exilby",{"value":712,"count":480},"EmpowHer Cannabis Society",{"value":714,"count":480},"Higher Love Cannabis Co.",{"value":716,"count":480},"Spec's Wine and Spirits & Finer Foods",{"value":718,"count":480},"Aery Group",{"value":720,"count":480},"R'belle",{"value":722,"count":480},"Curaleaf Inc.",{"value":724,"count":480},"Ascend Wellness Holdings Inc.",{"value":726,"count":480},"BamaBloom",{"value":728,"count":480},"Sunnyside",{"value":310,"count":480},{"value":75,"count":480},{"value":732,"count":480},"BevMo! by Gopuff",{"value":734,"count":480},"Beast Media",{"value":736,"count":480},"The Woods",{"value":738,"count":480},"Green Thumb Industries",{"value":740,"count":480},"Gramz",{"value":186,"count":480},{"value":743,"count":480},"HiWay",{"value":745,"count":480},"Cannabis Health",{"value":747,"count":480},"IPS Pharma",{"value":749,"count":480},"Decibel Cannabis",{"value":751,"count":480},"Dunbar Pharma",{"value":753,"count":480},"Square",{"value":755,"count":480},"Verano Holdings LLC",{"value":412,"count":480},{"value":758,"count":480},"Wana Brands",{"value":760,"count":480},"AYR Wellness Inc.",{"value":762,"count":480},"Team Winston",{"value":764,"count":480},"ABC Fine Wine & Spirits",{"value":766,"count":480},"Storz & Bickel",{"value":768,"count":480},"Rx Green Technologies",{"value":142,"count":480},{"value":771,"count":480},"High Rollers","2026-09-17T18:05:05.641Z"]